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Abstract
There is an increasing incidence of esophageal adenocarcinoma (EA) among younger people in the western populations.
However, the association between genetic polymorphisms and the age of EA onset is unclear. In this study, 1330 functional/
tagging single-nucleotide polymorphisms (SNPs) from 354 cancer-related genes were genotyped in 335 white EA patients.
Twenty important SNPs that have the highest importance scores and lowest classification error rate were identified by the
random forest algorithm to be associated with early onset of EA (age ≤ 55 years). Subsequent logistic regression analysis
indicated that 10 SNPs (rs2070744 ofNOS3, rs720321 of BCL2, rs17757541 of BCL2, rs11775256 of TNFRSF10A, rs1035142
of CASP8, rs2236302 of MMP14, rs4740363 of ABL1, rs696217 of GHRL, rs2445762 of CYP19A1, and rs11941492 of
VEGFR2/KDR) were significantly associated with early onset of EA (≤55 vs >55 years, all P < .05 after adjusting for co-
variates and false discovery rate). Among them, five SNPs in the NOS3, BCL2, TNFRSF10A, and CASP8 genes were known
to be involved in apoptosis processes. In Kaplan-Meier analyses, rs2070744 of NOS3, rs720321 of BCL2, and rs1035142 of
CASP8 were also significantly associated with early onset of EA. Moreover, there was a higher risk of developing EA at a
younger age when one had more risk genotypes. In conclusion, polymorphisms in cancer-related genes, especially those in
the apoptotic pathway, play an important role in the development of younger-aged EA in a dose-response manner.
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Introduction
The incidence of esophageal adenocarcinoma (EA) has increased
rapidly in the past few decades and surpassed that of squamous cell
carcinoma in many western countries [1]. There is a concomitant rise
in the numbers of young EA patients. Previous reviews showed that
such patients had more advanced disease at presentation compared
with those diagnosed at an older age [2,3]. This is probably because
current guidelines do not suggest urgent endoscopic examination in
dyspeptic patients younger than 55 years without alarm symptoms
such as chronic gastrointestinal bleeding, progressive weight loss, or
dysphagia [4,5]. However, once such symptoms develop, the disease
is usually in the advanced stages and inoperable. Factors contributing
to early onset of EA are still poorly understood.
The cause of early and late onset of esophageal cancer may be both
different and complex. Nevertheless, genetic variation may be an im-
portant variable for early onset cancers. An esophageal squamous cell
carcinoma (ESCC) study indicated that polymorphisms in ADH1B
and ALDH2 genes that are implicated in acetaldehyde elimination
can modify the risk of alcohol drinking in ESCC and can contribute
substantially to the early onset of ESCC [6]. A study of EA risk showed
that patients carrying the A870 allele in cyclin D1 had higher risk for
younger age of EA development [7]. However, investigation on poly-
morphisms of p53 Arg72Pro, MDM2 T309G, and CCND1 G870A
genes did not find any association between polymorphisms and age
of EA onset [8]. These observations suggest that a few number of
SNPs or genes may not be sufficient enough to define the contribution
of genetic factors to EA development because EA is a complex disease
likely involved in multiple genetic factors [9]. In this study, we sys-
tematically investigated the associations of genetic polymorphisms
with early onset of EA using a pathway-based approach that included
1330 functional/tagging SNPs in 354 cancer-related genes. Our hy-
pothesis is that patients who develop early onset of EA carry different
alleles in cancer-related genes compared with those who develop late
onset of EA.
Patients and Methods
Study Population and Interview
Three hundred thirty-five incident white patients were recruited into
this study. They were older than 18 years and histologically confirmed
to have EA at the Massachusetts General Hospital between 1999 and
2005 and at Dana-Farber Cancer Institute between 2004 and 2005. All
of them had a tumor center located at or above the gastroesophageal
junction and had at least two-thirds of the bulk tumor located in the
esophagus. Patients with secondary or recurrent cancers were excluded.
The recruitment rate was 86%. Details of patient recruitment were
described in our previous article [10,11]. Patients underwent upper
gastrointestinal endoscopy, esophagogram, and computed tomography
of chest and abdomen for staging workup. Clinicopathologic stage was
determined based on the TNM classification according to the Inter-
national Union Against Cancer [12].
All participants were interviewed using a modified questionnaire
[13] immediately after enrollment to collect information on their de-
mographic characteristics and history about gastroesophageal reflux
disease (GERD) symptoms and smoking. Lifetime GERD-related
symptoms were collected based on the questions described previously
[14]. The presence of GERD was defined as having heartburn or
regurgitation symptoms at least once per month for more than six
continuous months in one’s lifetime [10,14]. Smoking status was de-
fined based on whether the patient smoked 1 year before diagnosis.
Body weight and height at age 18 were obtained from each subject
in a self-reported manner, and the body mass index (BMI) was calcu-
lated accordingly.
Definition of Younger Age of Onset
Current guidelines use 55 years as the cutoff for recommendation
of urgent endoscopy referral [4,5]. This is based on the reports that
cancers of the upper gastrointestinal tract is detected in less than 1%
of western populations undergoing endoscopy for dyspepsia [15].
The incidence of EA in males younger than 55 years was less than
5 per 100,000, which doubled at age 65 years and peaked at the age
of 75 to 79 years (15/100,000) during 1973 to 2002 [1]. Here, we
use 55 years or younger as the definition of early onset of EA, as
suggested in previous reports [3].
DNA Preparation
Blood samples were collected at the time of recruitment, and DNA
was extracted using the Puregene DNA Isolation Kit (Gentra Systems/
Qiagen, Valencia, CA). The success rate in extracting DNAwas 100%.
This study was approved by the human subjects committees of Massa-
chusetts General Hospital, Dana-Farber Cancer Institute, and the
Harvard School of Public Health (Boston, MA). All subjects signed
the informed consent before study participation.
SNP Selection, Pathway Categorization, and Genotyping
A custom-designed Illumina GoldenGate platform was used. The
candidate SNPs in this study were common SNPs with minor allele
frequency ≥ 5% selected from the HapMap database of white popu-
lation (CEU). They were either missense/exonic SNPs, SNPs within
UTR regions, and 2 kb of the 5′ region of the gene, or tagSNPs. The
common nonsynonymous SNPs were selected from the databases of
the SNP500Cancer Project and International HapMap Project. Po-
tential functional nonsynonymous SNPs were selected from the PICS
(Predicted Impact of Coding SNPs) database and FASTSNP. SNPs
on the Illumina Cancer Panel were chosen with priority. TagSNPs were
selected using the r2-based Tagger program with pairwise r2 ≥ 0.80 and
minor allele frequency ≥ 5% among whites. The details for SNP selec-
tion in theGoldenGate assay was described previously [11]. Genotyping
was finished by February 2008 at the Broad Institute of Massachusetts
Institute of Technology and Harvard University. Of all cases, 97% were
successfully genotyped. Ninety-six DNA samples from patients with
early and later onset of EA were analyzed in each platform.
Genes in cancer-related pathway were chosen based on the litera-
ture reports and information in the National Center for Biotechnology
Information Genetic Association Database, National Institute for En-
vironmental Health Science GeneSNPs, and Kyoto Encyclopedia of
Genes and Genomes. More frequently cited genes were given greater
priority. Genotyping was performed on the Illumina GoldenGate
assay at the Broad Institute (Cambridge, MA) by laboratory personnel
blinded to the subjects’ clinical information. Forty-eight duplicate sam-
ples were randomly selected for quality control. In total, 1330 SNPs
(354 genes) categorized into 14 cancer-related pathways were success-
fully genotyped. The concordance rate of the replicate samples for all
assays was greater than 99%.
Statistical Analysis
Mean and SD were used to describe quantitative data, and propor-
tions are used to describe categorical data. The Student’s t and χ 2 tests
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were used to compare the means and proportions between early and
later onset groups.
To test the joint effects of SNPs in the same pathway, we used a
logistic kernel machine model. This method tests the association be-
tween outcome and a kernel function combining a set of SNPs, which
allows for flexible modeling of SNP effects [11]. An Identity-by-State
kernel was used to account for the relationship among SNPs.
For SNP-based analysis, we applied a three-step approach. First, we
used a random forest algorithm [16], using early or later onset as the
outcome and SNPs as the predictors, to impute the missing values
(<4% in each variable) and then obtained the mean decrease of accu-
racy (MDA) for each SNP. The MDA measures the degree of loss if
the corresponding SNP was “removed” from the model and could be
regarded as an “importance” score for the SNP. Second, the sliding win-
dows sequential forward feature selection method (SWSFS) was used
to identify the top important SNPs [17]. The SWSFS method includes
the SNPs one by one to the random forest model by the order of MDA
scores in step one. To minimize random bias, 100,000 trees were con-
structed, allowing each variable to have approximately 100% of the
probability tested 500 times. Then we plotted the “out of bagging”
error, which measured the performance of each model consisting of
different number of SNPs to identify a SNP set with the lowest error
rate for further analysis. Third, we performed a case-control univariate
logistic regression analysis using additive genetic model and multiple
logistic regressions for covariate adjustment. False discovery rates
(FDRs) were used to correct for multiple comparisons [18]. To esti-
mate the cumulative risk effects of the significant SNPs, we counted
the number of risk genotypes representing a genetic risk “score” and
used logistic models to find the contribution of the score to the risk
of early onset.
We also used Kaplan-Meier curves to describe the relationships be-
tween risks of onset on different ages and genotypes in dominant model
(mutant carriers vs wild-type homozygotes). Statistical significance was
tested using Cox proportional hazard models. The goodness of fit for
each model was tested using Hosmer-Lemeshow lack of fit test for
logistic regression. P > .10 was considered an acceptable goodness of
fit. All data analyses were performed using the SAS statistical package,
version 9.1 (SAS Institute, Cary, NC). Random forest analysis was per-
formed using rpart package in R software, version 2.9.1.
Results
Compared with those older than 55 years when diagnosed with cancer,
patients with younger age of EA onset had significantly higher BMI
(24.6 ± 4.4 vs 23.3 ± 3.5 kg/m2, P = .01) and later stage at diagnosis
(70.8% vs 55.3% in stage III-IV, P = .01; Table 1). In Cox regression
model, BMI greater than 25 kg/m2 was also significantly associated with
younger median age of EA onset (59.9 vs 65.4 years; relative risk, 1.30;
95% confidence interval [CI], 1.03-1.64; P = .03). The other major risk
factors of EA, namely sex, presence of GERD symptoms, GERD fre-
quency/duration, and smoking habit, were not significantly different
between these two groups (Table 1). Although 43 and 46 patients, re-
spectively, who had GERD symptoms did not provide adequate infor-
mation onGERD frequency and duration, their demographic data were
not statistically different in the two age groups (Tables W1 and W2).
Among the 14 pathways in this study, the apoptosis pathway re-
mained significant after correcting for multiple comparisons (nominal
P = .004, FDR = 0.05; Table 2). Although this pathway comprises the
most number of SNPs in our GoldenGate platform, the other two
pathways involving inflammation and carcinogens/procarcinogens
metabolism, which also includedmore than 200 SNPs, were not related
to the age of EA onset (Table 2).
In the random forest analysis, the importance score (MDA) for
each variable that quantifies the relative contribution of that variable
to the prediction accuracy was obtained (Figure 1). Interestingly, the
well-established EA risk factors such as smoking and GERD were not
listed in the top markers to discriminate early and later onset of EA.
The most important environmental factor recognized was BMI, which
only ranked 22 in this algorithm (Figure 1). The SWSFS algorithm
identified a set of 20 SNPs that had the lowest classification error rates
(Figure 2). Therefore, the top 20 SNPs with MDA greater than 1
shown in Figure 1 were selected for further logistic regression analysis,
which used subjects with later onset of EA (>55 years when diagnosed
with cancer) as reference.
Among the top 20 SNPs, 10 remained significantly associated with
age of cancer onset after adjusted for covariates and FDR (FDR < 0.05;
Table 3). Of the 10 SNPs, 4 were in apoptotic genes and the 2
(rs720321, rs17757541) in BCL2 were not in linkage disequilibrium
(correlation coefficient r2 = −0.04, P = .47). Compared with patients
diagnosed of EA at the age older than 55 years, the presence of variant
genotypes of these two SNPs in BCL2 was inversely associated with
younger age of EA onset (adjusted odds ratio [AOR] = 0.40-0.45,
FDR = 0.01-0.02). On the contrary, variant genotypes of NOS3
rs2070744 (AOR = 1.76, FDR = 0.01) and CYP19A1 rs2445762
(AOR = 1.63, FDR = 0.03), two SNPs categorized in carcinogen/
procarcinogen metabolism pathway, were significantly more prevalent
among younger EA patients. The results for the other SNPs are shown
in Table 3. The allele frequencies of the 10 significant SNPs are listed
in Table W3.
The age at EA diagnosis for the different genotypes (wide type vs
variants) of the 10 significant SNPs was analyzed separately using
Kaplan-Meier survival curves (Figure W1). The trend for each SNP
was consistent with that found in logistic regression models shown in
Table 3. NOS3 rs2070744 (FDR = 0.02), BCL2 rs720321 (FDR =
0.1), and CASP8 rs1035142 (FDR = 0.007) remained significant after
adjusting for FDR in a Cox regression model (Table W4). Therefore,
a combination of these three SNPs was used to evaluate the cumula-
tive risk of EA onset (Figure 3). We found that the median age at
Table 1. Characteristics of Early Onset and Later Onset EA Patients.
Characteristics Early Onset (≤55 Years),
n = 89
Later Onset (>55 years),
n = 246
P
Sex, male, n (%) 79 (88.8) 216 (87.8) .81
GERD,* yes, n (%) 42 (47.2) 131 (53.3) .33
Frequency of GERD, n (%), times/wk
≤2 19 (45.2) 48 (36.6) .07†
≥3 9 (21.4) 51 (38.9)
Unknown 14 (33.4) 32 (24.4)
Duration of GERD, n (%), years
≤10 10 (23.8) 46 (35.1) .34†
>10 19 (45.2) 55 (42.0)
Unknown 13 (31.0) 30 (22.9)
Ever smokers, yes, n (%) 66 (74.2) 203 (82.6) .09
BMI at age 18 (mean ± SD), kg/m2 24.6 ± 4.4 23.3 ± 3.5 .01
BMI ≥ 25 kg/m2 at age 18, n (%) 37 (42.6) 67 (27.2%) .01
Stage, n (%)
I-II 26 (29.2) 110 (44.7) .01
III-IV 63 (70.8) 136 (55.3)
*Seven (2%) missing and imputed.
†Not comparing those with missing data.
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EA diagnosis among patients with two and three risk genotypes was 5.4
and 9.2 years younger, respectively, than those with fewer than 1 risk
genotype (adjusted P for trend = 3.6 × 10−7) (Figure 3B).
Discussion
Although GERD is the strongest risk factor for EA, nearly 50% of EA
patients do not experience GERD-associated symptoms [19]. There-
fore, it is unlikely that GERD is the determinant factor for early onset
of EA. For instance, a previous study has showed that there was no dif-
ference in sex distribution, smoking history, or presence of GERD
symptoms between early and later onset of EA patients [20]. In our
study, we also observed that patients in both of early onset and later-
onset groups had similar frequency and duration of GERD symptoms,
suggesting that GERD was not a confounding factor for the effect of
genetic polymorphisms on the age of EA onset. Consistent with pre-
vious studies [3,21], we found a significantly higher proportion of stage
III, IV disease among younger-aged EA patients. This finding implies
that younger-aged patients are prone to be underdiagnosed or EA is
more aggressive if it develops at a younger age.
We used a case-only design, which had a greater power than case-
control study, to investigate the determinant SNPs discriminating early
and later onset of EA. To avoid false-positive results arising from the
correlation between significant candidate genotypes and age, we also
examined the independent and interactive effects of the top 10 SNPs
in a case-control manner (Table W5). The control subjects were de-
scribed in our previous study [11]. We found that the trend of the
interaction ORs in the case-control study was consistent with the ORs
in this case-only study, although not all of theP values in the case-control
model were significant (P < .05).
This is the first pathway-based genetic association study of patients
with early versus later onset EA. Our pathway analysis indicated that
the apoptosis pathway was important in distinguishing the two groups.
In addition, results from both logistic regression (Table 3) and survival
analysis (Figure W1) revealed that SNPs in the apoptotic pathway had
stronger association with early onset of EA than SNPs in other path-
ways. Apoptosis is essential for normal tissues to regulate cell number
and to eliminate DNA-damaged or aging cells as an organism develops.
Evading apoptosis, a characteristic of transformed cells, has been well
documented in the carcinogenesis of EA [22,23]. Previous studies have
linked polymorphisms in apoptotic genes to different risks of esopha-
geal cancer [11,14,24]. In the current analysis, four SNPs in three
apoptotic genes (BCL2, CASP8, and TNFRSF10A) were significantly
associated with younger-aged EA. BCL2 protein is one of the prod-
ucts of BCL2 family, which has both proapoptotic and antiapoptotic
functions. BCL2 protein has been found aberrantly expressed in EA car-
cinogenesis [25,26]. TNFRSF10A, or TNF-related apoptosis-inducing
ligand (TRAIL) receptor 1, is one of the cognate receptors that binds
to TNF superfamily ligands to activate caspase 8 and 10, thus initiating
the caspase cascade of extrinsic apoptotic pathway [27]. Genetic poly-
morphisms in the apoptotic genes such as BCL2 have been found to be
implicated in certain aging-related diseases, such as Alzheimer disease,
in which progressive cellular apoptosis leads to brain dysfunction [28].
Table 2. Associations of Pathways with Susceptibility to Early Onset (Age ≤ 55 Years) of EA.
Pathway No. Genes No. SNPs Nominal P * FDR
Apoptosis 41 233 .004 0.05
Cell signaling 28 82 .03 0.22
Telomere maintenance 1 5 .07 0.31
Angiogenesis 15 140 .09 0.31
Cell growth 30 64 .18 0.48
DNA methylation 4 14 .23 0.48
Immunity 10 20 .24 0.48
Molecular transport 8 16 .28 0.49
Metastasis 15 17 .54 0.84
Cell cycle control 48 149 .70 0.93
Inflammation 37 219 .80 0.93
Carcinogen/procarcinogen metabolism 71 208 .86 0.93
Sex hormone signaling 11 65 .86 0.93
DNA repair 51 129 .95 0.95
*Pathway-based analysis assessed by the logistic kernel machine regression.
Figure 1. Importance score plot of top 40 SNPs selected from 1330 SNPs using the random forest algorithm. Higher MDA means higher
contribution to the prediction of early onset. MDA was estimated from 100,000 trees.
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In animal models of myocardial infarction, cardiomyocyte apoptosis
activities among older rats were higher than that of younger rats [29].
Two SNPs (rs2070744 of NOS3 and rs2445762 of CYP19A1) in
the carcinogen/procarcinogen metabolism pathway were also asso-
ciated with younger-aged EA. The product of endothelial constitu-
tive nitric oxide synthase 3 (NOS3) is one of the isoforms of NO
synthases, which catalyze the formation of NO. NOS3 participates
in many immunologic processes including apoptosis [30]. There-
fore, NOS3 is an apoptosis-related gene, although it is categorized
in the carcinogen/procarcinogen metabolism pathway in this study.
Overexpression of NOS3 has been detected in esophageal adeno-
carcinoma, especially those with advanced diseases (T3/4, positive
nodal metastasis, and stage III/IV) [31]. Cytochrome P450 aroma-
tase, the product of CYP19, is an enzyme that catalyzes the synthe-
sis of estrogens from androgens. Genetic variants in CYP19A1 have
been linked to hormone-related cancers, especially prostate and breast
cancers [32,33].
We also found significant associations between polymorphisms in
VEGFR2/KDR, ABL1, GHRL, and MMP14 and early onset of EA.
Gockel et al. [34] reported positive immunostaining of VEGFR2/
KDR, a receptor tyrosine kinase related to angiogenesis, in 94% (47/
50) of human EA tissues. However, the protein expressions of the other
three genes in EA or Barrett metaplasia are not clear. Polymorphisms in
VEGFR2/KDR and a cell cycle gene, ABL1, are related to many human
cancers but rarely studied in esophageal cancer. GHRL is an obesity-
related gene. rs696217, a missense SNP in GHRL, has been reported
to have modest association with EA risk (AOR, 1.69; 95% CI, 1.14-
2.50; P = .2 after Bonferroni correction) [35].Matrix metalloproteinases
(MMPs) are proteases that digest the extracellular matrix and con-
tribute to cancer invasion and metastasis. rs2236302 of MMP14 is a
Figure 2. Prediction error rate of 1330 SNPs using early onset (≤55 years) of EA as outcome. The x-axis denotes the number of SNPs in
the model, where the SNPs are included one by one based on their MDA ranks ranging from the most (left) to the least (right) impor-
tance. The y-axis is the error rate estimated from 100, 000 trees by random forest analysis. A set of 20 SNPs that had the lowest error
rates (0.23) was selected for further logistic regression analysis.
Table 3. Associations between the Top 20 SNPs* and Early Onset (≤55 Years) of EA.
SNP Reference Genotype Gene Pathway AOR (95% CI)† P† FDR†
rs2070744 CC NOS3 Carcinogen/procarcinogen metabolism 1.76 (1.25-2.48) .001 0.01
rs2236302 CC MMP14 Metastasis 0.27 (0.12-0.61) .002 0.01
rs720321 GG BCL2 Apoptosis 0.40 (0.23-0.72) .002 0.01
rs4740363 AA ABL1 Cell cycle control 0.16 (0.05-0.53) .003 0.01
rs11775256 CC TNFRSF10A Apoptosis 1.79 (1.20-2.68) .004 0.02
rs17757541 CC BCL2 Apoptosis 0.45 (0.26-0.78) .005 0.02
rs696217 GG GHRL Cell growth 0.27 (0.10-0.71) .008 0.02
rs1035142 GG CASP8 Apoptosis 0.61 (0.42-0.89) .010 0.02
rs2445762 CC CYP19A1 Carcinogen/procarcinogen metabolism 1.63 (1.11-2.41) .014 0.03
rs11941492 CC VEGFR2/KDR Angiogenesis 1.58 (1.07-2.32) .020 0.04
rs4149570 GG TNFRSF1A Apoptosis 1.46 (1.02-2.08) .037 0.07
rs1110277 GG SLC23A2 Molecular transport 1.48 (1.01-2.16) .04 0.07
rs11244142 AA ABL1 Cell cycle control 1.63 (1.01-2.63) .04 0.07
rs11196422 GG CASP7 Apoptosis 1.55 (0.97-2.47) .06 0.09
rs6097809 TT CYP24A1 Carcinogen/procarcinogen metabolism 1.87 (0.88-3.99) .10 0.14
rs1234220 TT PTEN Apoptosis 1.60 (0.87-2.94) .13 0.16
rs640180 GG FGFR4 Angiogenesis 1.34 (0.90-2.00) .15 0.17
rs1801265 CC DPYD Carcinogen/procarcinogen metabolism 1.33 (0.86-2.05) .20 0.22
rs3808815 CC ABL1 Cell cycle control 1.33 (0.74-2.38) .34 0.35
rs543215 AA PGR Sex hormone signaling 0.10 (0.61-1.56) .93 0.93
*Twenty SNPs that have the highest importance scores and lowest classification error rate were identified by random forest from among 1330 functional/tagging SNPs in 14 pathways.
†Adjusted odds ratio used patients younger than 55 years as the reference; adjusted for sex, BMI at age 18 years (<25 vs ≥25), GERD (+/−), and smoking (never/ever); FDR < 0.05 was defined as significant.
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synonymous SNP that is located in exon 5.However, its associationwith
cancer has not been reported.
Moreover, a combination of NOS3 rs2070744, BCL2 rs720321,
and CASP8 rs1035142 significantly discriminate the early and later
onset of EA. The cumulative risk for developing EA at a younger age
increases when more risk genotypes in these three apoptosis-related
genes are present. This result further supports the importance of genetic
variants in apoptosis pathway in the early onset of EA. Although many
significant SNPs identified in this study were tag SNPs located in
introns with unclear functions, it was interesting that most of those
genes are involved in the earlier stage of cancer formation, such as path-
ways involving carcinogen metabolism, cell cycle control, cell growth,
and apoptosis (Table 3).
We acknowledge that our study has several limitations. First, the case
number in this study is relatively small because EA is an uncommon
disease even among whites. However, we have more than 80% power
to identify a significant effect of the SNPs if the minor allele frequency
approaches 10% and an association OR of 1.45 [36]. Second, we were
not able to replicate in another population because no other data set
is available at this stage. Third, there is lack of information about the
presence of Barrett esophagus in our patients. Last, the generalization
of our results to other ethnic population or histologic types (e.g., SCC)
of esophageal cancer should be used with caution because we only
included white EA patients.
In conclusion, this study suggests that polymorphisms in cancer-
related genes, especially SNPs in apoptotic pathway, may play an im-
portant role in the early onset of EA. In addition to the typical alarm
symptoms in current clinical guidelines, this set of three SNPs has the
potential to become a clinical tool to screen for those at high risk of EA
at a relatively young age. Previous studies have reported overexpression
of NOS3, BCL2, and VEGFR2/KDR in EA tissues, supporting their
role in Barrett carcinogenesis. Replication in other populations and fur-
ther studies are required to validate our results and to elucidate the
functions of important SNPs, individually or jointly, in relation to early
onset of EA.
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Table W1. Demographic Characteristics of 43 Patients with GERD Symptoms but Did Not Provide
the Duration Information.
Characteristics ≤55 Years (n = 13) >55 Years (n = 30) P
Sex, male, n (%) 11 (84.6) 24 (80.0) .32*
Smoking, yes, n (%) 10 (76.9) 25 (83.3) .28*
BMI at age 18 (mean ± SD), kg/m2 25.4 ± 5.8 24.3 ± 3.5 .23
BMI ≥ 25 kg/m2 at age 18, n (%) 7 (53.9) 10 (33.3) .21
Stage, n (%) .49
I-II 5 (38.5) 15 (50.0)
III-IV 8 (61.5) 15 (50.0)
*Fisher exact test.
Table W2. Demographic Characteristics of 46 Patients with GERD Symptoms but Did Not Provide
the Frequency Information.
Characteristics ≤55 Years (n = 14) >55 Years (n = 32) P
Sex, male, n (%) 12 (85.7) 27 (84.4) 1.00
Smoking, yes, n (%) 10 (71.4) 27 (84.4) .42
BMI at age 18 (mean ± SD), kg/m2 26.1 ± 5.7 24.7 ± 4.1 .36
BMI ≥ 25 kg/m2 at age 18, n (%) 7 (50.0) 12 (37.5) .52
Stage, n (%)
I-II 5 (35.7) 17 (53.1) .35
III-IV 9 (64.3) 15 (46.9)
Table W3. Allele Frequencies of the SNPs Significantly Associated with Age of EA Onset.
SNP ≤55 Years (n = 89), % >55 Years (n = 246), %
AA AB BB AA AB BB
NOS2 rs2070744 19.1 51.7 29.2 40.7 39.8 19.5
MMP14 rs2236302 92.1 7.9 0 75.2 24.4 0.4
BCL2 rs720321* 82.0 16.9 1.1 64.2 32.9 2.9
ABL1 rs4740363 96.9 3.4 0 82.9 15.9 1.2
TNFRSF10A rs11775256 47.2 43.8 9.0 64.6 30.9 4.5
BCL2 rs17757541* 80.9 18.0 1.1 64.6 31.7 3.7
GHRL rs696217 94.4 5.6 0 81.3 18.3 0.4
CASP8 rs1035142 50.6 37.1 12.4 33.7 50.0 16.3
CYP19A1 rs2445762 46.1 41.6 12.3 58.5 36.6 4.9
VEGFR2/KDR rs11941492 52.8 32.6 14.6 58.9 36.2 4.9
*Correlation coefficient of the two SNPs r2 = −0.04, P = .47.
Figure W1. Kaplan-Meier curves: cumulative risk and age of cancer diagnosis associated with the wide-type (ww) or variant types (vv + vw)
of the 10 SNPs.
Table W4. COX Regression Model of the 10 SNPs.
SNP OR (95% CI) P FDR
NOS2 rs2070744 1.40 (1.13-1.76) .004 0.02
MMP14 rs2236302 0.84 (0.64-1.10) .196 0.28
BCL2 rs720321 0.77 (0.61-0.97) .029 0.10
ABL1 rs4740363 0.82 (0.60-1.13) .226 0.28
TNFRSF10A rs11775256 1.21 (0.97-1.50) .093 0.23
BCL2 rs17757541 0.94 (0.75-1.19) .619 0.69
GHRL rs696217 0.80 (0.59-1.07) .137 0.27
CASP8 rs1035142 0.68 (0.54-0.85) .0007 0.007
CYP19A1 rs2445762 1.02 (0.82-1.26) .868 0.87
VEGFR2/KDR rs11941492 1.16 (0.93-1.44) .185 0.28
Table W5. Independent and Interactive ORs of the Top 10 SNPs and Age on EA Risk among 335 Cases and 319 Controls.
SNP* Age ≤ 55 Years Age > 55 Years Interaction OR* (95% CI) P
OR P OR P
NOS2 rs2070744 3.69 (1.45-9.38) .006 0.75 (0.46-1.20) .228 4.02 (1.57-10.29) .004
MMP14 rs2236302 0.29 (0.09-0.91) .033 1.65 (0.94-2.89) .081 0.20 (0.06-0.65) .008
BCL2 rs720321 0.78 (0.34-1.81) .565 1.54 (0.94-2.53) .084 0.54 (0.21-1.36) .191
ABL1 rs4740363 0.08 (0.02-0.44) .003 1.06 (0.57-1.98) .861 0.12 (0.02-0.62) .011
TNFRSF10A rs11775256 1.72 (0.84-3.53) .136 1.07 (0.67-1.70) .787 1.48 (0.66-3.32) .336
BCL2 rs17757541 0.41 (0.17-0.98) .044 0.76 (0.47-1.21) .247 0.61 (0.24-1.53) .297
GHRL rs696217 0.63 (0.17-2.38) .495 1.46 (0.79-2.69) .230 0.40 (0.10-1.61) .195
CASP8 rs1035142 0.81 (0.40-1.63) .554 1.06 (0.65-1.71) .821 0.73 (0.32-1.65) .450
CYP19A1 rs2445762 2.06 (1.01-4.17) .046 0.79 (0.50-1.25) .317 2.40 (1.08-5.34) .032
VEGFR2/KDR rs11941492 1.25 (0.62-2.53) .535 0.86 (0.54-1.37) .527 1.44 (0.65-3.18) .371
*SNPs in dominant model and age dichotomized by 55 years.
